Although human HSCs share CD34+ without CD38, the majority of AML blasts express CD38.10, 11 Accordingly, we focused on CD38 as a candidate therapeutic target and developed anti-CD38-CAR. The gene discussed is CD38; the disease is acute myeloid leukemia.